Immuno-Oncology | Specialty

Dr. Petrylak on Ongoing Investigations of Checkpoint Inhibition in Bladder Cancer

January 31st 2017

Daniel P. Petrylak, MD, professor of Medicine and Urology, Yale Cancer Center, discusses immune checkpoint inhibitors that are currently being evaluated for the treatment of patients with bladder cancer.

Immuno-Oncology Will Require Extensive Staff Training

January 30th 2017

Immuno-oncology drugs have the potential to improve the level of care in many respects, but they bring with them a host of problems related to implementation that require a completely new set of strategies.

Dr. Zhang on Challenges With Vaccines in Renal Cell Carcinoma

January 28th 2017

Tian Zhang, MD, a medical instructor in the Department of Medicine, Duke University School of Medicine, discusses some of the challenges associated with administering vaccines to patients with renal cell carcinoma.

Dr. Sklar on Immunotherapy Potential in Bladder Cancer

January 28th 2017

Geoffrey Sklar, MD, Chief Medical Officer, Chesapeake Urology Associates, discusses the potential of immunotherapy agents in the treatment of patients with bladder cancer.

Dr. Rosenberg on Frontline Immunotherapy Potential in Bladder Cancer

January 27th 2017

Jonathan E. Rosenberg, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the potential that immunotherapy has in the frontline setting for patients with bladder cancer.

Dr. Motzer on the Milestone of Immunotherapy in RCC

January 27th 2017

Robert J. Motzer, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, 2016 Giant of Cancer Care in Genitourinary Cancer, discusses the explosion of immunotherapy in the landscape of renal cell carcinoma (RCC).

Dr. Chiorean on Combination Therapies for Pancreatic Cancer

January 26th 2017

Gabriela Chiorean, MD, associate professor of Medicine at the University of Washington, discusses adverse events of the phase I study of combination therapies for patients with pancreatic cancer.

Underreporting of Immunotherapy-Related AEs a Concern in RCC

January 24th 2017

Neeraj Agarwal, MD, discusses a trend of underreporting and underemphasizing toxicities associated with PD-1 inhibitors in the treatment of patients with renal cell carcinoma.

Nivolumab Activity Affirmed in Microsatellite Instability-High mCRC

January 24th 2017

The promising antitumor activity of nivolumab in patients with microsatellite instability-high metastatic colorectal cancer was sustained in an update of the phase II CheckMate-142 trial.

Dr. Pal on Preoperative Immunotherapy in Patients With RCC

January 24th 2017

Sumanta Kumar Pal, MD, medical oncologist, assistant clinical professor, Department of Medical Oncology and Therapeutics Research, co-director, Kidney Cancer Program, City of Hope, discusses the potential with immunotherapy in the preoperative setting for patients with renal cell carcinoma.

Expert Discusses 2-Year Update of Pivotal Nivolumab RCC Trial

January 24th 2017

Elizabeth Plimack, MD, discusses updated data from the pivotal CheckMate-025 trial, which compared the use of nivolumab with everolimus in the treatment of patients with metastatic renal cell carcinoma.

Dr. Seiwert on Next Steps in Treatment of Patients With Head and Neck Cancer

January 24th 2017

Tanguy I. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses the next steps researchers are taking to improve survival outcomes for patients with head and neck cancer.

Researcher Hopes Vaccines Can Improve Immunotherapy Outcomes in RCC

January 23rd 2017

Tian Zhang, MD, discusses the development of vaccines to treat patients with renal cell carcinoma.

Dr. Abou-Alfa Discusses Ongoing Studies of Immunotherapy in HCC

January 22nd 2017

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses ongoing studies investigating immunotherapy in hepatocellular carcinoma.

Dr. Chau on Ramucirumab Plus Pembrolizumab for Gastric/GEJ Cancer

January 21st 2017

Ian Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses interim safety and clinical activity results in patients with advanced gastric or gastroesophageal junction adenocarcinoma from a multi-cohort phase I study of ramucirumab plus pembrolizumab.

Frontline Immunotherapy Combo Setbacks Strike NSCLC

January 21st 2017

Bristol-Myers Squibb and AstraZeneca have each announced separate delays in the development of PD-1 and CTLA-4 inhibitor combinations as first-line therapies for patients with advanced or metastatic non–small cell lung cancer.

PD-1/VEGF Combos a Next Step for RCC Treatment

January 20th 2017

David F. McDermott, MD, discusses ongoing efforts to improve outcomes in advanced renal cell carcinoma through combination anti–VEGF/PD-1 regimens.

Pembrolizumab/Ramucirumab Combo Active in Gastric Cancers

January 20th 2017

A combination regimen of pembrolizumab plus ramucirumab demonstrated modest activity in patients with previously treated gastric or gastroesophageal juncture cancer.

Dr. Borghaei on Reporting Immunotherapy-Related AEs in Lung Cancer

January 20th 2017

Hossein Borghaei, DO, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses how physicians can help patients with lung cancer feel more comfortable reporting adverse events (AEs) associated with immunotherapy.

Nivolumab Improves Survival in Advanced Gastric/GEJ Cancer

January 20th 2017

Treatment with nivolumab reduced the risk of death by 37% compared with placebo for patients with advanced gastric or gastroesophageal junction cancer following second or later-line chemotherapy.